A
Adynxx, Inc. (ADYX)
PNK – Real Time Price. Currency in USD
0.00
0.00 (0.00%)
At close: Sep 7, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
PNK – Real Time Price. Currency in USD
0.00
0.00 (0.00%)
At close: Sep 7, 2026, 4:00 PM EDT
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
| Name | Position |
|---|---|
| Mr. Richard Orr Esq., J.D. | President, CEO, Principal Financial Officer & Director |
| Mr. William Martin | Executive Vice President of Corporate Development & Operations |
| Ms. Dina Gonzalez | Principal Accounting Officer & Senior VP of Finance |
| Ms. Kimberley Hebert | Senior Director of Clinical Operations |
| Date | Type | Document |
|---|---|---|
| 2023-04-27 | DEF 14A | formdef14a.htm |
| 2023-03-28 | 10-K | form10-k.htm |
| 2023-03-27 | 8-K | form8-k.htm |
| 2023-03-23 | 8-K | form8-k.htm |
| 2023-03-02 | 8-K | form8-k.htm |
| 2023-01-17 | 8-K | form8-k.htm |
| 2023-01-06 | 8-K | form8-k.htm |
| 2022-12-07 | 8-K | form8-k.htm |
| 2022-11-08 | 8-K | form8-k.htm |
| 2022-09-09 | 8-K | form8-k.htm |